Bayer

July 18, 2023

The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer and Merck

Illumina Inc., in collaboration with Nashville Biosciences LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, have announced the five founding new members of the Alliance for Genomic Discovery.

By VUMC News and Communications
Shown here are members of the team working to evaluate new drug candidates for the treatment of kidney diseases.
October 6, 2022

Kidney diseases research collaboration renewed

Vanderbilt University Medical Center and Bayer have agreed to continue a strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases.

By Nancy Humphrey
September 11, 2017

Vanderbilt, Bayer collaborate to develop new therapies against kidney diseases

Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.

By VUMC News and Communications